{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008304","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.850169+00:00","generated_at":"2026-06-18T00:55:43.130390+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monte Rosa reports FY 2022 net loss of $108.5M; MRT-2359 Phase 1/2 data expected H2 2023","bullets":["FY 2022 net loss $108.5M (vs $74.0M in 2021); cash & securities $268.1M, runway into 2025.","MRT-2359 Phase 1/2 ongoing; initial Phase 1 PK/PD/safety data expected H2 2023.","FDA granted Fast Track for MRT-2359 in pretreated metastatic NSCLC with L-MYC/N-MYC expression.","VAV1 degrader advanced to lead optimization; multiple development candidates expected in 2023.","Promoted Jennifer Champoux to Chief People & Operations Officer; appointed Magnus Walter SVP Chemical Sciences."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008304","json":"https://secwatch.observer/filing/0000950170-23-008304.json","markdown":"https://secwatch.observer/filing/0000950170-23-008304.md","text":"https://secwatch.observer/filing/0000950170-23-008304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023008304/0000950170-23-008304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023008304/glue-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:55:43.130390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb317b93993f812ca12e4bf303c7c828f12416a0","claim":"Monte Rosa Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 16, 2023, Monte Rosa Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023008304/0000950170-23-008304-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}